Given anti-psychosis precedents set earlier with mianserin, it is likely Sanofi (SNY) and Lilly (LLY) considered the potential for a psychiatric "triple application" for their compounds. It raises the prospect that if Acadia does …
Article by Mianserin – Google Blog Search. Read entire story here.
News and insights about GAD, depression, phobias, OCD and panic attacks